GH Research (GHRS)
NASDAQ:GHRS
Want to see GHRS full AI Analyst Report?
Top Page
GH Research
(NASDAQ:GHRS)
Select Model
Select Model
Rating:52Neutral
Price Target:
$22.50
▲(22.68% Upside)
Action:Reiterated
Date:04/23/26
The score is held back primarily by weak financial performance (no revenue, widening losses, and ongoing cash burn), partly offset by a strong, low-leverage balance sheet. Technicals are supportive with clear upward trend and positive momentum, while valuation remains a drag due to negative earnings and no dividend.
Positive Factors
Balance sheet strength
Very low leverage and sizable equity provide durable financial flexibility to fund late‑stage trials and device development without immediate refinancing pressure, reducing short‑term solvency risk and supporting multi‑quarter R&D execution.
Negative Factors
Pre‑revenue with widening losses
Absence of product revenue and accelerating net losses reflect continued dependence on R&D spending with no commercialization offsets; over multiple quarters this reduces return on equity and heightens reliance on external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Very low leverage and sizable equity provide durable financial flexibility to fund late‑stage trials and device development without immediate refinancing pressure, reducing short‑term solvency risk and supporting multi‑quarter R&D execution.
Read all positive factors
GH Research (GHRS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.52B
Dividend YieldN/A
Average Volume (3M)172.07K
Price to Earnings (P/E)―
Beta (1Y)1.13
Revenue GrowthN/A
EPS Growth-5.50%
CountryUS
Employees50
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.80
Shares Outstanding68,557,175
10 Day Avg. Volume103,362
30 Day Avg. Volume172,068
Financial Highlights & Ratios
PEG Ratio-3.01
Price to Book (P/B)2.77
Price to Sales (P/S)0.00
P/FCF Ratio-17.75
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.73K
Enterprise Value/Ebitda-24.27
Forecast
1Y Price Target
$40.13Price Target Upside118.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.46
Revenue Forecast (FY)N/A
GH Research Business Overview & Revenue Model
Company Description
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therap...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, GH Research does not have publicly disclosed recurring revenue from product sales. The company’s operations are primarily funded through external financing, including proceeds from equity offerings (s...
GH Research Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
30
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -335.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -60.34M | -38.60M | -35.21M | -22.41M | -9.17M |
| Net Income | -48.26M | -38.96M | -35.59M | -22.46M | -9.20M |
Balance Sheet | |||||
| Total Assets | 288.23M | 188.27M | 226.30M | 254.36M | 279.92M |
| Cash, Cash Equivalents and Short-Term Investments | 280.71M | 149.32M | 161.56M | 165.96M | 276.78M |
| Total Debt | 512.00K | 624.00K | 974.00K | 0.00 | 0.00 |
| Total Liabilities | 8.53M | 9.32M | 7.33M | 4.55M | 2.75M |
| Stockholders Equity | 279.70M | 178.95M | 218.97M | 249.82M | 277.18M |
Cash Flow | |||||
| Free Cash Flow | -43.67M | -42.33M | -33.44M | -26.27M | -15.39M |
| Operating Cash Flow | -43.55M | -42.28M | -33.34M | -26.20M | -15.28M |
| Investing Cash Flow | 46.17M | 65.14M | -54.10M | -84.69M | -104.00K |
| Financing Cash Flow | 139.65M | -304.00K | -204.00K | 0.00 | 286.45M |
GH Research Technical Analysis
Positive
18.34
Price Trends
15.21
Positive
14.96
Positive
14.41
Positive
Market Momentum
0.69
Negative
72.21
Negative
91.79
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GHRS, the sentiment is Positive. The current price of 18.34 is above the 20-day moving average (MA) of 14.99, above the 50-day MA of 15.21, and above the 200-day MA of 14.41, indicating a bullish trend. The MACD of 0.69 indicates Negative momentum. The RSI at 72.21 is Negative, neither overbought nor oversold. The STOCH value of 91.79 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GHRS.
GH Research Risk Analysis
GH Research disclosed 104 risk factors in its most recent earnings report. GH Research reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GH Research Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $1.81B | -9.66 | -56.07% | ― | 3.42% | -11.04% | |
56 Neutral | $927.06M | -55.77 | 4.75% | ― | 15.66% | ― | |
52 Neutral | $1.52B | -13.93 | -16.30% | ― | ― | -5.50% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $2.45B | -6.10 | -43.94% | ― | 39.04% | 29.88% | |
43 Neutral | $873.84M | -4.22 | -141.99% | ― | ― | -6.15% | |
42 Neutral | $565.33M | -3.14 | -188.82% | ― | 4.89% | 24.20% |
* Healthcare Sector Average
GHRS
GH Research
21.39
10.41
94.81%
RLAY
Relay Therapeutics
12.20
9.39
334.16%
TSHA
Taysha Gene Therapies
5.96
3.26
120.74%
SANA
Sana Biotechnology
3.07
1.33
76.44%
PHAR
Pharming Group
12.92
3.61
38.78%
PRME
Prime Medicine, Inc.
2.93
1.34
84.28%
GH Research Corporate Events
GH Research Launches $200 Million At-the-Market Share Offering With Stifel
May 14, 2026
On May 14, 2026, GH Research PLC entered into an at-the-market equity offering sales agreement with Stifel, Nicolaus Company to sell up to $200 million of its ordinary shares from time to time. The shares are registered under an existing Form F-3...
GH Research Posts Wider Q1 2026 Loss as R&D and Admin Costs Rise
May 14, 2026
On May 14, 2026, GH Research PLC filed a Form 6-K in the United States reporting its first-quarter 2026 results and providing business updates, alongside posting an updated investor presentation. The filing also furnished unaudited condensed conso...
GH Research Sets June 25, 2026 AGM and Tables Board, Auditor Votes
May 13, 2026
GH Research has called its 2026 annual general meeting for June 25, 2026, in Dublin, inviting shareholders of record as of May 1, 2026 to attend, vote and review the company’s 2025 Irish statutory financial statements. The company has circul...
GH Research to Attend APA Annual Meeting in San Francisco in May 2026
May 13, 2026
GH Research PLC announced on May 13, 2026, that it will attend the American Psychiatric Association Annual Meeting in San Francisco, California. The conference is scheduled to take place from May 16 to May 20, 2026, and the company’s partici...
GH Research Raises $111 Million in Completed Share Offering to Fund Depression Pipeline
Apr 30, 2026
On April 30, 2026, GH Research PLC completed an underwritten public offering of 6,527,779 ordinary shares at $18.00 per share, raising estimated net proceeds of about $111.2 million after fees. The transaction, priced a day earlier and led by Stif...
GH Research Publishes Phase 2b GH001 TRD Data and Highlights Severity-Independent Efficacy
Mar 25, 2026
On March 25, 2026, GH Research PLC reported that full results from its randomized, double-blind, placebo-controlled Phase 2b trial of mebufotenin (GH001) in treatment-resistant depression have been published and peer-reviewed in JAMA Psychiatry. T...
GH Research to Join Stifel 2026 Virtual CNS Forum Fireside Chat
Mar 16, 2026
On March 16, 2026, GH Research PLC reported that it will take part in a fireside chat at the Stifel 2026 Virtual CNS Forum, a sector-focused event scheduled to be held online from March 17 to 18, 2026. The planned participation underscores the com...
GH Research Posts 2025 Results as TRD Drug GH001 Clears Key Phase 2b Milestone
Mar 5, 2026
GH Research PLC reported on March 5, 2026, that it completed a successful Phase 2b trial of its inhaled mebufotenin candidate GH001 in treatment-resistant depression in 2025, demonstrating rapid and durable remission rates with a strong safety pro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.